昂利康(002940) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥359,329,021.98, representing a 1.75% increase year-over-year, while the year-to-date revenue reached ¥1,063,113,569.06, up 7.72% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2022 was ¥29,171,223.85, a significant increase of 203.43% year-over-year, with a year-to-date net profit of ¥108,275,724.51, reflecting a 44.00% increase[4] - The basic earnings per share for Q3 2022 was ¥0.31, marking a 210.00% increase compared to the same period last year, while the diluted earnings per share also stood at ¥0.31[4] - Total operating revenue for the third quarter reached ¥1,063,113,569.06, an increase of 7.8% compared to ¥986,885,462.15 in the same period last year[25] - The net profit for the third quarter of 2022 was CNY 113,440,888, an increase of 23.5% compared to CNY 91,813,306 in the same period last year[26] - The operating profit for the quarter was CNY 125,537,781, up from CNY 118,904,972, reflecting a growth of 5.4%[26] - The total revenue from sales of goods and services reached CNY 1,304,612,965, compared to CNY 1,142,063,944 in the previous year, marking an increase of 14.2%[27] - Basic and diluted earnings per share for the quarter were both CNY 1.15, up from CNY 0.78 in the previous year, representing a growth of 47.4%[27] - The total comprehensive income attributable to the parent company was CNY 108,275,725, compared to CNY 75,194,012 in the same period last year, reflecting a growth of 43.9%[26] Assets and Liabilities - The company's total assets as of September 30, 2022, were ¥2,427,816,704.62, a 16.52% increase from the end of the previous year[4] - Current assets decreased to ¥1,284,732,436.21 from ¥1,375,955,724.32, indicating a reduction in liquidity[22] - Total liabilities rose to ¥851,494,145.14 from ¥608,642,637.36, indicating increased financial obligations[23] - The company's equity attributable to shareholders increased to ¥1,432,424,818.35 from ¥1,338,853,095.62, reflecting retained earnings growth[23] Cash Flow - The net cash flow from operating activities for the first nine months of 2022 was ¥213,947,191.32, a 37.19% increase year-over-year, driven by higher cash receipts from sales[9] - The cash flow from operating activities generated a net amount of CNY 213,947,191, which is an increase of 37.2% from CNY 155,946,945 in the same period last year[27] - The company's cash flow from financing activities for the first nine months of 2022 was ¥200,579,871.01, a notable change from a cash outflow of ¥130,561,802.81 in the previous year, primarily due to new bank loans[9] - The financing activities resulted in a net cash inflow of CNY 200,579,871, reversing the outflow of CNY 130,561,803 from the same period last year[29] - The cash and cash equivalents at the end of the period were CNY 603,970,655, down from CNY 733,663,744 at the end of the previous year[29] Investments - The company reported a 503.00% increase in long-term equity investments, totaling ¥546,571,677.93, due to increased investments in joint ventures[8] - The company’s net profit from investment activities for the first nine months of 2022 was ¥7,502,078.82, a significant improvement compared to a loss of ¥14,467,528.91 in the same period last year[9] - The company reported an investment income of ¥7,502,078.82, a recovery from a loss of ¥14,467,528.91 in the previous year[25] - The company has completed the acquisition of 15.74% of Keri Bio-Pharmaceutical Co., Ltd. for RMB 157.48 million[14] - The company plans to acquire an additional 38.22% of Keri Bio-Pharmaceutical Co., Ltd. for RMB 191.30 million, pending shareholder approval[16] - The company has engaged in a strategic investment in Guangdong Yiduoli Biotechnology Co., Ltd. for RMB 200 million[13] Shareholder Information - The total number of common shareholders at the end of the reporting period is 9,259[11] - The largest shareholder, Shenzhou Juntai Investment Co., Ltd., holds 35.44% of shares, totaling 34,000,000 shares, with 13,825,000 shares pledged[11] - The top ten shareholders collectively hold 60.30% of the company's shares, indicating a concentrated ownership structure[12] Research and Development - Research and development expenses for the first nine months of 2022 amounted to ¥66,481,632.41, an increase of 82.54% compared to the same period in 2021, indicating a significant investment in innovation[9] - Research and development expenses increased significantly to ¥66,481,632.41, compared to ¥36,419,433.88 in the previous year, reflecting a focus on innovation[25] Inventory and Accounts Payable - The company experienced a 141.59% increase in accounts payable, reaching ¥232,839,776.00, attributed to an increase in issued payables during the reporting period[8] - Inventory levels increased to ¥371,298,600.06, up from ¥299,602,396.21, suggesting a buildup of stock[22]